Clinical trial
Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and…
NCT00148837 · French National Agency for Research on AIDS and Viral Hepatitis, Other · Unknown status
Key facts
| NCT number | NCT00148837 |
|---|---|
| Title | Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis |
| Official title | Randomized Double Blind Trial Comparing the Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin for Initial Treatment of Patients With Hepatitis C With Genotype 1 or 4 and Severe Fibrosis |
| Lead sponsor | French National Agency for Research on AIDS and Viral Hepatitis, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic, Fibrosis |
| Intervention type | Drug |
| Interventions | Peg-interferon alpha 2b (drug), Ribavirin (drug), Prazosin (drug) |
| Enrollment | 112 |
| Start date | Sep 1, 2004 |
| First posted | Sep 8, 2005 |
| Last update posted | Feb 8, 2008 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: